Loading patent…
AssigneeQuantum Genomics
InventorsCatherine Llorens-Cortes, Yannick Marc, Ji Gao-Desliens, Fabrice Balavoine, Lionel Segard
Estimating the term…
The present invention relates to a pharmaceutical composition comprising, in at least one pharmaceutically acceptable support or vehicle, a combination of (3S,3S′)4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) or a pharmaceutically acceptable salt or solvate thereof and a second active ingredient selected from the group consisting of angiotensin I converting enzyme inhibitors and angiotensin II receptor type I antagonists. Said composition is particularly useful for the treatment of hypertension and related diseases and conditions.
A method for treatment of arterial hypertension or indirectly or directly related diseases, wherein said method comprises orally administering to a subject in need of such treatment an effective amount of a combination of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) or a pharmaceutically acceptable salt or solvate thereof and enalapril, wherein an hypotensive effect occurs within the first 2 hours after administration of said combination, and wherein the weight ratio of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) relative to enalapril is 100/1.
Dependencies are inferred from the claim text.